Our sister site, Drug Delivery Business News, reports today that the continuous glucose monitor (CGM)-based offering received clearance for adults with type 2 diabetes on glargine U-100 long-acting insulin therapy. San Diego-based Dexcom says it marks the first and only CGM-integrated basal dosing optimizer cleared for type 2 diabetes.
Smart Basal uses Dexcom’s G7 15 Day sensor data and logged doses to calculate personalized daily recommendations. It guides users toward a more effective long-acting insulin dose, as directed by their healthcare provider.
Dexcom — one of the largest diabetes tech companies in the world — designed its new offering to begin with an initial base insulin dose set by a healthcare provider. Users then receive daily dose recommendations and reminders in their G7 15 Day app. The platform looks at all of the user’s CGM readings to adjust personalized dose recommendations. This differs from the conventional use of a single fasting blood glucose measurement, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
Visit here to purchase our Medtech Market Special Report on CGMs.
